Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

64. Absolute Monocyte Count (AMC) as Early and Safe Marker for Discharge in Low-risk Pediatric Febrile Neutropenia with Cancer

View through CrossRef
Abstract Background Fever with neutropenia (FN) is common and the timing of antibiotic cessation in patients without an identified fever source is uncertain. Absolute neutrophile count (ANC) recovery has been used clinically to represent bone marrow recovery (BMR) but other options should be considered. We hypothesized that absolute monocyte count (AMC), and absolute phagocyte count (APC) are more sensitive, and an earlier safe marker of antibiotic cessation (AC) compared with ANC Methods A retrospective review was performed for FN episodes (FNEs) at UCM Comer Children’s Hospital between 2009 and 2016 in pediatric oncology patients. Eligible FNEs who were a febrile for 24 hours, had no bacterial source identified at time of AC, and did not receive chemotherapy 10 days following AC. Ten-day post-AC outcomes, length of stay and cost were assessed and compared among different BMR parameters (ANC vs AMC). Results A total of 928 FN episodes (FNEs) were identified. 391 eligible FNEs occurred in 235 patients. Three groups were compared based on ANC (cells/μL) at the time of AC : < 200 in 102 (26%), 200-500 in 111 (28%), and >500 /uL in 178 (46%) (Figure1) with an overall ten-day recurrent fever rate 7.4% (29/391) and readmission rate of 5.6% (22/391). No significant differences in recurrent fever rates were identified among 3 ANC groups (11.7%, 6.3% and 5.6% respectively, P=0.08) and readmission (10%,4.5%, 4%, respectively; P=0.07)(Table 1).In subset analysis of AMC for each ANC group, patients with AMC >100 at AC have favorable outcomes, regardless ANC threshold (P< 0.01) (Table 1). Median of length of stay of FN was 3 days shorter using AMC >100/uL for BMR compared with any threshold of ANC (P< 0.01) and decrease overall FN cost stay (P< 0.01) (Table 2). Similar analysis show APC >300/uL at time of AC has favourable outcomes and decrease LOS regardless ANC threshold (data not shown here). Conclusion Our results suggest that a AMC > 100 /uL regardless of ANC/uL, is a safe threshold value for empiric AC and discharge. This approach may shorten length of stay, reduce burden of cost of febrile neutropenia cost and potential long term antibiotics side effects. Disclosures Lara Danziger-Isakov, MD, MPH, Ansun (Individual(s) Involved: Self): Scientific Research Study Investigator; Astellas (Individual(s) Involved: Self): Scientific Research Study Investigator; Merck (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator; Pfizer (Individual(s) Involved: Self): Scientific Research Study Investigator; Shire (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator; Viracor: Grant/Research Support
Title: 64. Absolute Monocyte Count (AMC) as Early and Safe Marker for Discharge in Low-risk Pediatric Febrile Neutropenia with Cancer
Description:
Abstract Background Fever with neutropenia (FN) is common and the timing of antibiotic cessation in patients without an identified fever source is uncertain.
Absolute neutrophile count (ANC) recovery has been used clinically to represent bone marrow recovery (BMR) but other options should be considered.
We hypothesized that absolute monocyte count (AMC), and absolute phagocyte count (APC) are more sensitive, and an earlier safe marker of antibiotic cessation (AC) compared with ANC Methods A retrospective review was performed for FN episodes (FNEs) at UCM Comer Children’s Hospital between 2009 and 2016 in pediatric oncology patients.
Eligible FNEs who were a febrile for 24 hours, had no bacterial source identified at time of AC, and did not receive chemotherapy 10 days following AC.
Ten-day post-AC outcomes, length of stay and cost were assessed and compared among different BMR parameters (ANC vs AMC).
Results A total of 928 FN episodes (FNEs) were identified.
391 eligible FNEs occurred in 235 patients.
Three groups were compared based on ANC (cells/μL) at the time of AC : < 200 in 102 (26%), 200-500 in 111 (28%), and >500 /uL in 178 (46%) (Figure1) with an overall ten-day recurrent fever rate 7.
4% (29/391) and readmission rate of 5.
6% (22/391).
No significant differences in recurrent fever rates were identified among 3 ANC groups (11.
7%, 6.
3% and 5.
6% respectively, P=0.
08) and readmission (10%,4.
5%, 4%, respectively; P=0.
07)(Table 1).
In subset analysis of AMC for each ANC group, patients with AMC >100 at AC have favorable outcomes, regardless ANC threshold (P< 0.
01) (Table 1).
Median of length of stay of FN was 3 days shorter using AMC >100/uL for BMR compared with any threshold of ANC (P< 0.
01) and decrease overall FN cost stay (P< 0.
01) (Table 2).
Similar analysis show APC >300/uL at time of AC has favourable outcomes and decrease LOS regardless ANC threshold (data not shown here).
Conclusion Our results suggest that a AMC > 100 /uL regardless of ANC/uL, is a safe threshold value for empiric AC and discharge.
This approach may shorten length of stay, reduce burden of cost of febrile neutropenia cost and potential long term antibiotics side effects.
Disclosures Lara Danziger-Isakov, MD, MPH, Ansun (Individual(s) Involved: Self): Scientific Research Study Investigator; Astellas (Individual(s) Involved: Self): Scientific Research Study Investigator; Merck (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator; Pfizer (Individual(s) Involved: Self): Scientific Research Study Investigator; Shire (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator; Viracor: Grant/Research Support.

Related Results

Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
AMC: A Short Story
AMC: A Short Story
On March 15, 2021, a senior hedge fund analyst was tasked with formulating an investment thesis for AMC Entertainment (AMC). The stock had been highly volatile as the US economy em...
Outcome of Febrile Neutropenia in Children with Cancer: Experience from a Tertiary Health Care Center
Outcome of Febrile Neutropenia in Children with Cancer: Experience from a Tertiary Health Care Center
Background: Febrile neutropenia (FN) is a serious event in children with cancer; associated with various complications and mentionable adverse outcome.Objective: To identify the ou...
The prevalence of neutropenia in chemotherapy cancer patients at a provincial hospital, Thailand
The prevalence of neutropenia in chemotherapy cancer patients at a provincial hospital, Thailand
Abstract Introduction Cancer patients with neutropenia (<1500 cell/mm3 absolute neutrophil count [ANC]) are at high risk ...
A Single-Center Large Cohort of Chronic Neutropenia Patients and a Model for Estimation of Congenital Neutropenias
A Single-Center Large Cohort of Chronic Neutropenia Patients and a Model for Estimation of Congenital Neutropenias
Chronic neutropenia (CrN) is defined as neutropenia lasting longer than 3 months and has various underlying etiologies, including congenital neutropenia (CN). We aimed to determine...
Frequency of a Positive Cerebrospinal Fluid Study in Patients Presenting With Febrile Seizures
Frequency of a Positive Cerebrospinal Fluid Study in Patients Presenting With Febrile Seizures
Background: Febrile seizures are a common neurological condition in pediatric practice, affecting 2-5% of children globally. These seizures occur in the context of fever without ev...
ROLE OF HAEMATOLOGY BIOMARKERS IN URINARY BLADDER AND RENAL CELL CANCER PATIENTS TREATED WITH IMMUNE-ONCOLOGICAL DRUGS
ROLE OF HAEMATOLOGY BIOMARKERS IN URINARY BLADDER AND RENAL CELL CANCER PATIENTS TREATED WITH IMMUNE-ONCOLOGICAL DRUGS
Background: Urinary bladder (UB) and Renal Cell Cancer (RCC) are common in men than women with poor outcome. The novel immunotherapy drugs like Immune Check Point Inhibitors (ICIs)...

Back to Top